Telemedicine's Second Act: What Comes After the Pandemic Boom

    After explosive growth during COVID-19, telemedicine is maturing into a permanent fixture of healthcare delivery.

    ByDr. Maya Krishnan

    The pandemic forced a rapid adoption of telemedicine that compressed years of change into months. Now, as the healthcare system settles into its new normal, the question is: what does telemedicine 2.0 look like?

    From Emergency Measure to Standard Care

    Telemedicine usage surged 38x during the pandemic peak. While volumes have normalized, they remain 5-8x higher than pre-pandemic levels. More importantly, both patients and providers have shifted their attitudes permanently.

    The Integration Challenge

    The next phase of telemedicine isn't about standalone video visits — it's about seamless integration with in-person care, remote monitoring, and AI-driven diagnostics. The winners will be organizations that create truly hybrid care models.

    Regulatory Landscape

    Policy decisions will play a crucial role in telemedicine's evolution. Questions around interstate licensing, reimbursement parity, and prescribing regulations remain unresolved and will shape the industry's trajectory.

    More from Healthcare & Medicine

    Healthcare & Medicine

    Ahead of Thanksgiving, Readers Show Grace and Grit

    KFF Health News gives readers a chance to comment on a recent batch of stories.

    By KFF Health News · November 19, 2026
    Healthcare & Medicine

    STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more

    Merck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technology

    By Ed Silverman · November 19, 2026
    Healthcare & Medicine

    What’s Behind a Recent Spike in Early Social Security Claims?

    Experts point to well-publicized turmoil at the government agency last year as a potential spark.

    By Paula Span · November 19, 2026
    Healthcare & Medicine

    Opinion: STAT+: I’m a cardiologist. I’m a little puzzled about the blockbuster new study on deprescribing statins

    STAT columnist Vishal Khetpal examines the STREAM trial and its findings about discontinuing use of statins.

    By Vishal Khetpal · November 19, 2026
    Healthcare & Medicine

    Meet the Teen Who Called a Hospital Home

    A young survivor of gun violence lived on the third floor of a St. Louis children’s hospital, moving through the halls in a wheelchair, on and off for over three years. He said it became his home when he had nowhere safe to go.

    By Cara Anthony · November 18, 2026
    Healthcare & Medicine

    STAT+: Epic Systems defends competitive practices, promises to let AI access its records

    Executives from Epic, the largest electronics health records vendor, defended its competitive practices during a panel discussion at HLTH.

    By Casey Ross and Matthew Herper · November 19, 2026
    Healthcare & Medicine

    Trump Administration OKs Native Traditional Healing for Two States’ Medicaid Programs

    The administration’s expansion of traditional healing for Native Americans comes as it shrinks Medicaid in other ways, including through restrictions that will affect access to care for an estimated 7.5 million people.

    By Jazmin Orozco Rodriguez · November 18, 2026
    Healthcare & Medicine

    STAT+: FDA discloses reasons for rejecting Summit drug

    The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

    By Elaine Chen and Adam Feuerstein · November 18, 2026
    Healthcare & Medicine

    Moving to a New State? Your Healthcare Might Get More Complicated

    New apartment, new friends, new … healthcare hurdles? Medical matters might not be at the top of your list when moving to a new state. But planning ahead will help you get the health insurance, doctors, and healthcare access you need.

    By Katherine Ruppelt, Nashville Public Radio, Cara Anthony and Blake Farmer, Nashville Public Radio · November 17, 2026
    Healthcare & Medicine

    STAT+: Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’

    Bill Cassidy's rejection of Jim O'Neill comes shortly after the White House pulled FDA commissioner nominee Heidi Overton.

    By Daniel Payne and Margaret Manto · November 18, 2026